Javascript must be enabled to continue!
Performance of PRECISE-DAPT and Age–Bleeding–Organ Dysfunction Score for Predicting Bleeding Complication During Dual Antiplatelet Therapy in Chinese Elderly Patients
View through CrossRef
BackgroundRecently, the Age–Bleeding–Organ Dysfunction (ABO) algorithm was recommended by the Asian Pacific Society of Cardiology Consensus as a binary approach to evaluate bleeding risk. This analysis made comparison of the predictive performances between the PRECISE-DAPT and ABO bleeding score in identifying the risk of 12-months major bleeding in Chinese elderly patients over 65 years old patients who underwent percutaneous coronary intervention (PCI) during dual-antiplatelet therapy period.MethodsA total of 2,037 elderly coronary artery disease (CAD) patients (≥65 years) receiving dual antiplatelet therapy (DAPT) after PCI were enrolled in the study. The predictive accuracy of the two bleeding risk scores (PRECISE-DAPT and ABO) was compared for identifying the risk of bleeding during the dual-antiplatelet therapy in patients who underwent PCI. Major clinically relevant bleeding events were defined according to the Bleeding Academic Research Consortium (BARC) criteria.ResultsThe PRECISE-DAPT score in the no bleeding, BARC = 1 bleeding, BARC ≥ 2 bleeding patients was 23.55 ± 10.46, 23.23 ± 10.03, and 33.54 ± 14.33 (p < 0.001), respectively. Meanwhile, the ABO score in the three groups was 0.72 ± 0.80, 0.69 ± 0.81, and 1.49 ± 0.99 (p < 0.001), respectively. The C-statistic of the PRECISE-DAPT model for prediction of BARC ≥ 2 bleeding in overall patients was 0.717 (95% CI, 0.656–0.777) and 0.720 (95% CI, 0.656–0.784) in acute coronary syndrome (ACS) patients. Similar discriminatory capacity was demonstrated in the ABO risk score [overall, patients, AUC: 0.712 (95% CI, 0.650–0.774); ACS patients, AUC: 0.703 (95% CI, 0.634–0.772)]. No differences were observed when the ABO model was in comparison with the PRECISE-DAPT model, regardless in overall patients (z = −0.199, p = 0.842) or ACS patients (z = −0.605, p = 0.545). The calibration for BARC ≥ 2 bleeding of the PRECISE-DAPT and ABO score were acceptable, regardless in overall patients [goodness-of-fit (GOF) Chi-square = 0.432 and 0.001, respectively; p-value = 0.806 and 0.999, respectively] or ACS patients (GOF Chi-square = 0.008 and 0.580, respectively; p-value = 0.996 and 0.748, respectively).ConclusionNo matter of clinical presentation in Asian 65-years older patients with DAPT, the PRECISE-DAPT, and ABO scores had the similar discriminative ability for 12-months BARC ≥ 2 bleeding. Considering the simplicity and reliability, the PRECISE-DAPT score might be more clinically applicable in the overall population and ACS patients in bleeding prediction.
Title: Performance of PRECISE-DAPT and Age–Bleeding–Organ Dysfunction Score for Predicting Bleeding Complication During Dual Antiplatelet Therapy in Chinese Elderly Patients
Description:
BackgroundRecently, the Age–Bleeding–Organ Dysfunction (ABO) algorithm was recommended by the Asian Pacific Society of Cardiology Consensus as a binary approach to evaluate bleeding risk.
This analysis made comparison of the predictive performances between the PRECISE-DAPT and ABO bleeding score in identifying the risk of 12-months major bleeding in Chinese elderly patients over 65 years old patients who underwent percutaneous coronary intervention (PCI) during dual-antiplatelet therapy period.
MethodsA total of 2,037 elderly coronary artery disease (CAD) patients (≥65 years) receiving dual antiplatelet therapy (DAPT) after PCI were enrolled in the study.
The predictive accuracy of the two bleeding risk scores (PRECISE-DAPT and ABO) was compared for identifying the risk of bleeding during the dual-antiplatelet therapy in patients who underwent PCI.
Major clinically relevant bleeding events were defined according to the Bleeding Academic Research Consortium (BARC) criteria.
ResultsThe PRECISE-DAPT score in the no bleeding, BARC = 1 bleeding, BARC ≥ 2 bleeding patients was 23.
55 ± 10.
46, 23.
23 ± 10.
03, and 33.
54 ± 14.
33 (p < 0.
001), respectively.
Meanwhile, the ABO score in the three groups was 0.
72 ± 0.
80, 0.
69 ± 0.
81, and 1.
49 ± 0.
99 (p < 0.
001), respectively.
The C-statistic of the PRECISE-DAPT model for prediction of BARC ≥ 2 bleeding in overall patients was 0.
717 (95% CI, 0.
656–0.
777) and 0.
720 (95% CI, 0.
656–0.
784) in acute coronary syndrome (ACS) patients.
Similar discriminatory capacity was demonstrated in the ABO risk score [overall, patients, AUC: 0.
712 (95% CI, 0.
650–0.
774); ACS patients, AUC: 0.
703 (95% CI, 0.
634–0.
772)].
No differences were observed when the ABO model was in comparison with the PRECISE-DAPT model, regardless in overall patients (z = −0.
199, p = 0.
842) or ACS patients (z = −0.
605, p = 0.
545).
The calibration for BARC ≥ 2 bleeding of the PRECISE-DAPT and ABO score were acceptable, regardless in overall patients [goodness-of-fit (GOF) Chi-square = 0.
432 and 0.
001, respectively; p-value = 0.
806 and 0.
999, respectively] or ACS patients (GOF Chi-square = 0.
008 and 0.
580, respectively; p-value = 0.
996 and 0.
748, respectively).
ConclusionNo matter of clinical presentation in Asian 65-years older patients with DAPT, the PRECISE-DAPT, and ABO scores had the similar discriminative ability for 12-months BARC ≥ 2 bleeding.
Considering the simplicity and reliability, the PRECISE-DAPT score might be more clinically applicable in the overall population and ACS patients in bleeding prediction.
Related Results
The effect of co-treatment with DAPT and oxaliplatin on the biological behavior of human ovarian cancer stem cells
The effect of co-treatment with DAPT and oxaliplatin on the biological behavior of human ovarian cancer stem cells
Abstract
To assess the effects of the combination of DAPT and oxaliplatin on the biological behavior of human ovarian cancer stem cells. In vitro cultured human ovarian can...
226 DUAL ANTI-PLATELET THERAPY: AUDIT OF COMMUNICATION OF DIAGNOSIS AND DURATION ACROSS PRIMARY AND SECONDARY CARE
226 DUAL ANTI-PLATELET THERAPY: AUDIT OF COMMUNICATION OF DIAGNOSIS AND DURATION ACROSS PRIMARY AND SECONDARY CARE
Abstract
Background
Dual Anti-Platelet Therapy (DAPT) is indicated in vascular disease & duration of treatment depends on fa...
Abstract 67: Effects of Single vs Dual Antiplatelet Therapy on Long Term Stroke and Death After Carotid Endarterectomy
Abstract 67: Effects of Single vs Dual Antiplatelet Therapy on Long Term Stroke and Death After Carotid Endarterectomy
Introduction:
Current evidence suggests that dual antiplatelet therapy (DAPT) reduces perioperative stroke, but increases bleeding after carotid endarterectomy (CEA). T...
Impact of dual antiplatelet non-adherence after percutaneous coronary intervention in patients with or without history of myocardial infarction
Impact of dual antiplatelet non-adherence after percutaneous coronary intervention in patients with or without history of myocardial infarction
Abstract
Funding Acknowledgements
Type of funding sources: None.
OnBehalf
...
Multiple antiplatelet therapy in ischemic stroke already on antiplatelet agents
Multiple antiplatelet therapy in ischemic stroke already on antiplatelet agents
Abstract
Background: Optimal antiplatelet strategy for patients with ischemic stroke who were already on single antiplatelet therapy (SAPT) remains to be elucidated. This s...
Single vs Double Antiplatelet Therapy for Recurrent Ischemic Stroke Prevention
Single vs Double Antiplatelet Therapy for Recurrent Ischemic Stroke Prevention
Background: Ischemic stroke remains a leading cause of mortality and long-term disability, with recurrent events contributing significantly to the global disease burden. While sing...
Edoxaban and Cancer-Associated Venous Thromboembolism: A Meta-analysis of Clinical Trials
Edoxaban and Cancer-Associated Venous Thromboembolism: A Meta-analysis of Clinical Trials
Abstract
Introduction
Cancer patients face a venous thromboembolism (VTE) risk that is up to 50 times higher compared to individuals without cancer. In 2010, direct oral anticoagul...
Impact of Proton Pump Inhibitor Use on Efficacy of Dual Antiplatelet Therapy in Post-PCI Patients: A Meta-Analysis of Randomized Controlled Trials
Impact of Proton Pump Inhibitor Use on Efficacy of Dual Antiplatelet Therapy in Post-PCI Patients: A Meta-Analysis of Randomized Controlled Trials
Background: Dual antiplatelet therapy (DAPT) is a standard treatment following percutaneous coronary intervention (PCI), significantly reducing ischemic events but increasing gastr...

